source
- GSK to buy Nuvalent for $10.6B, gaining two lung-cancer drugs under FDA reviewGSK announced it will acquire Nuvalent, a biotech focused on lung cancer, in a transaction valued at about $10.6 billion. The deal gives GSK control of Nuvalent’s two experimental lung-cancer ther…
- GSK to acquire Nuvalent for $11 billion, adding two lung-cancer drugs under FDA reviewGSK announced a deal to buy Massachusetts‑based biotech Nuvalent for $11 billion. The acquisition brings two experimental lung‑cancer medicines that are currently under review by the U.S. Food and…